Study Design
EVENTS
In this prospective, multicenter, open-label, active-controlled, feasibility equivalence and noninferiority trial, oral rivaroxaban and subcutaneous enoxaparin were applied to patients with ACS who missed the primary reperfusion window (index events >12 or 48 hours) or before selective revascularization. The ATLAS ACS-TIMI 46 trial